NASDAQ · TOI
The Oncology Institute, Inc.
$5.13-$1.26 (-19.72%)
The Oncology Institute, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
Loading market information…
NASDAQ · PIII · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
P3 Health Partners Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
P3 Health Partners Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$3.97. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow P3 Health Partners Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. The company operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | -$6.28-25.6% vs estimate | $373.23M+6.69% vs estimate |
|---|
| Q4 2024 | Mar 27, 2025 | -$16.00-88.24% vs estimate | $370.69M-2.16% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$15.50-933.33% vs estimate | $362.12M-4.42% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $18.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.13-$1.26 (-19.72%)
The Oncology Institute, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
$1.07-$0.02 (-1.83%)
Talphera, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.85% below the high.
$3.51+$0.51 (+16.83%)
Hyperion DeFi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.95% below the high.
$0.81+$0.01 (+1.17%)
iBio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.7% below the high.
$3.16-$0.02 (-0.63%)
TAO Synergies Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.89% below the high.
$3.87-$0.13 (-3.25%)
Plus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.48% below the high.
$3.34-$0.04 (-1.09%)
Intensity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.32% below the high.
$4.75+$0.15 (+3.26%)
Basel Medical Group Ltd Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 74.95% below the high.
